EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W H Zhang, Xiaopeng Ma und 3 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202500181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Keke Ma und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen, 518026, China. Hauptthemen laut MEDLINE: Receptors, Antigen, T-Cell, Immunotherapy, Proto-Oncogene Proteins p21(ras), Single-Chain Antibodies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell receptor (TCR) based immunotherapy is an attractive strategy to target a wide range of intra‐tumoral antigens and elicit robust tumor cytotoxicity. However, engineering soluble TCR engagers that preserve physiological affinity is crucial for universal TCR drug development, yet remains challenging. In the present study, multiple TCR engagers featuring diverse architectures based on the KRAS‐G12V specific 1–2C TCR in the context of HLA‐A*11:01 is designed and evaluated. Notably, a soluble tandem double single‐chain TCR (STanD‐scTCR) engager, comprising two repeated single‐chain variable fragment (scFv) TCRs, exhibit enhanced binding avidity and potent T‐cell activation. Through site‐directed mutagenesis, T96F mutation (T96F‐TCR) within the TCR β chain is identified, which substantially augment T cell reactivity while maintaining physiological affinity and minimizing off‐target cross‐reactivity. The T96F‐mutated STanD‐scTCR engager demonstrates improved antigen sensitivity, promotes multi‐functional T‐cell responses, and facilitates immune synapse formation between T cells and target cells. In a xenograft tumor model harboring the KRAS‐G12V mutation, the TCR engager displays substantial tumor suppression efficacy. These findings underscore the therapeutic potential of 1–2C STanD‐scTCR engage in targeting KRAS‐G12V mutations in the context of HLA‐A*11:01. Furthermore, the engineering strategies employ in the development of STanD‐scTCR engager provide an invaluable for future designs of TCR engager drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Antigen, T-CellImmunotherapyProto-Oncogene Proteins p21(ras)Single-Chain AntibodiesNeoplasmsAnimalsHumansMiceCell Line, TumorT-Lymphocytes

Stichwörter der Autor:innen

KRAS‐G12V mutationTCR engagersfine‐tuned TCR affinitytumor inhibition

Substanzen

Receptors, Antigen, T-CellProto-Oncogene Proteins p21(ras)KRAS protein, humanSingle-Chain Antibodies

Autor:innen und Institutionen

  • Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen, 518026, China.
  • CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, 100101, China.
  • Innovative Vaccine and Immunotherapy Research Center, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China.
  • Medical School, University of Chinese Academy of Sciences, Beijing, 100101, China.
  • YKimmu (Beijing) Biotechnology Co., Ltd, Beijing, 100000, China.
  • Department of Immunology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, 100045, China.

ORCID-Profile: Shuguang Tan

Förderung

  • National Natural Science Foundation of China
  • Chinese Academy of Sciences
  • Guangdong Basic and Applied Basic Research Foundation
  • National Key Research and Development Program of China
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Ma, K., Wang, J., Jiang, M., He, J., Li, F., Lu, D., Su, C., Chai, Y., Jin, W., Chen, Y., Zhang, C. W. H., Ma, X., Tan, H., Gao, G. F., & Tan, S. (2025). An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202500181

Vancouver

Ma K, Wang J, Jiang M, He J, Li F, Lu D, et al. An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy. Advanced Science. 2025. doi:10.1002/advs.202500181

BibTeX
@article{Ma2025,
  author = {Ma, Keke and Wang, Jie and Jiang, Min and He, Juanhua and Li, Fangyang and Lu, Dan and Su, Chao and Chai, Yan and Jin, Wenjing and Chen, Yu and Zhang, Catherine W H and Ma, Xiaopeng and Tan, Hui and Gao, George F and Tan, Shuguang},
  title = {An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202500181}
}
Kostenlos starten →